Theracryf Interim Earnings Report

Theracryf EPS Results

• Actual EPS: -GBX 6
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Theracryf Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Theracryf Announcement Details

• Quarter: Interim
• Date: 12/3/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Theracryf (LON:TCF) is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.